Kuroda, Tatsuhiko http://orcid.org/0000-0002-2261-309X
Shiraki, Masataka http://orcid.org/0000-0001-6599-6185
Nakamura, Toshitaka
Suzuki, Hiroaki http://orcid.org/0000-0001-8005-9659
Hiraishi, Kazuki http://orcid.org/0000-0002-9368-9614
Sugimoto, Toshitsugu http://orcid.org/0000-0003-0627-1816
Tanaka, Satoshi http://orcid.org/0000-0001-8192-5125
Funding for this research was provided by:
Asahi Kasei Pharma Corporation
Article History
Received: 22 April 2021
Accepted: 30 July 2021
First Online: 24 August 2021
Declarations
:
: Tatsuhiko Kuroda is an employee of Asahi Kasei Corporation. Masataka Shiraki has received consulting fees from Asahi Kasei Pharma Corporation, MSD, and Teijin Pharma and lecture fees from Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Ono Pharmaceutical, and Pfizer. Toshitaka Nakamura has received consulting fees from Asahi Kasei Pharma Corporation, Amgen, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, MSD, Taisho Toyama Pharmaceutical, and Teijin Pharma. Hiroaki Suzuki, Kazuki Hiraishi, and Satoshi Tanaka are employees of Asahi Kasei Pharma Corporation. Toshitsugu Sugimoto has received research grants and/or consulting fees from Astellas Pharma, Eisai, Daiichi Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan as well as consulting and/or lecture fees from Asahi Kasei Pharma Corporation and Daiichi Sankyo.
: This study was conducted in compliance with the World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects and Good Clinical Practice. The protocol was reviewed by the institutional review board at each study site.
: Written informed consent was obtained from all individual subjects before enrollment in the study.
: All participants gave their written informed consent for the publication of the data in an anonymized form.